Drugs / Timolol
Timolol
also known as
timolol maleate · Timoptic · Aquanil · Betim · Betimol · Blocadren · Fixed Dose Combination of tafluprost and timolol · Geltim LP · +31 more
Other / unclassified targets ADRB1, ADRB2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | BLOCADREN | — | 1985-02-25 – 2009-03-13 | fda.gov ↗ |
| Label expansion | US (FDA) | TIMOLOL MALEATE | — | 2007-06-08 | fda.gov ↗ |
| Approved | EU (EMA) | DuoTrav | — | 2006-04-23 | europa.eu ↗ |
| Approved | US (FDA) | TIMOPTIC | — | 1978-08-17 | fda.gov ↗ |
Trials 120 · started per year
today
US approved 1978
EU approved 2006
1
1
1
3
4
1
11
6
4
3
8
5
11
6
2
7
5
5
3
5
4
4
7
1
3
2
2
4
1978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07474883 | Mar → Aug 2026 overdue | acne | Pham Ngoc Thach University of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT02697318 | May 2016 → Sep 2017 | glaucoma | University of Waterloo | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT07036510 | Jun 2025 → Jan 2027 expected | ocular hypertension, open-angle glaucoma | EyeD Pharma | Recruiting | No outcome recorded |
| Phase 1 | NCT06941467 | Jan 2025 → Jan 2027 expected | — | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06813807 | Jun → Jul 2024 | — | Auson Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06321562 | Mar 2023 → Jun 2025 | open-angle glaucoma | EyeD Pharma | Terminated | No outcome recorded |
| Phase 1 | NCT06824948 | Oct → Dec 2018 | — | Auson Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02852057 | Jan 2018 → Aug 2021 | glaucoma | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT02967614 | Dec 2016 → Dec 2017 | glaucoma, ocular hypertension | Kukje Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02774590 | Mar 2016 → Mar 2021 | acne, rosacea | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01434849 | Jul 2012 → Apr 2016 | hemangioma | Alice K. Gong | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01607671 | Jun 2012 → Nov 2013 | anterior ischemic optic neuropathy | Fraser Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01533376 | Feb 2012 → Jan 2019 | Sturge-Weber syndrome | Wills Eye | Terminated | No outcome recorded |
| Phase 1 | NCT00879099 | Apr 2009 → Jan 2010 | — | Santen Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02742649 | Apr → Dec 2016 | ocular hypertension, open-angle glaucoma | ForSight Vision5, Inc. | Completed | No outcome recorded |
| Phase 219 trials · 4 met primary · 2 missed | ||||||
| Phase 2 | NCT07384767 | Jun 2026 → Sep 2027 expected | — | University of California, Davis | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT04910100 | Apr 2021 → Mar 2022 | ocular hypertension, open-angle glaucoma | Betaliq, Inc. | Completed | Missed primary |
| Phase 2 | NCT05114239 | Apr 2021 → Sep 2022 | — | Keith G. LeBlanc, Jr, MD | Unknown | No outcome recorded |
| Phase 2 | NCT04139018 | Oct 2019 → May 2020 | hereditary hemorrhagic telangiectasia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02913612 | May 2017 → Oct 2020 | hemangioma | Kanecia Obie Zimmerman | Completed | Met primary |
| Phase 2 | NCT03836664 | Feb 2017 → Apr 2018 | migraine disorder | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02214680 | Oct 2015 → Aug 2016 | — | Carmel Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02484716 | Jun 2015 → Nov 2017 | hereditary hemorrhagic telangiectasia | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 2 | NCT02422017 | Apr 2015 → May 2016 | ulcer of lower limbs | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 2 | NCT02145884 | May 2014 → Oct 2016 | hemangioma | Rady Children's Hospital, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT02731287 | Mar 2014 → Jan 2017 | hemangioma | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01408056 | Feb 2011 → Jan 2014 | hemangioma | Children's Hospital of Philadelphia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00832377 | Apr 2009 → Mar 2010 | glaucoma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT00572936 | Mar 2006 → Nov 2009 | glaucoma | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00287521 | Nov 2005 → Feb 2006 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00368602 | Jun 2005 → Jun 2007 | ulcer disease | University of California, Davis | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00579969 | Dec 2003 → Oct 2008 | glaucoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 2 | NCT00317577 | Dec 1998 → May 2004 | open-angle glaucoma | Chicago Center for Vision Research | Completed | Met primary |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT06677853 | Oct 2020 → Jun 2022 | hemangioma | Auson Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03579160 | Jan 2019 → Jan 2022 | — | Brigham and Women's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03452072 | Aug 2018 → Dec 2020 | — | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 330 trials · 5 met primary · 1 missed | ||||||
| Phase 3 | NCT05503901 | Aug 2022 → Jan 2024 | open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04898387 | Mar 2021 → Apr 2023 | ocular hypertension | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT03822559 | Jan 2019 → Apr 2023 | open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03282981 | Jul 2018 → Dec 2023 | chronic ulcer of skin | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT02250651 | Dec 2014 → Oct 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | Met primary |
| Phase 3 | NCT02247804 | Dec 2014 → Feb 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01284166 | Jul 2013 → May 2014 | glaucoma, ocular hypertension | Allergan | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01685398 | Sep 2012 → Mar 2023 | hemangioma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT01746602 | Jul 2011 → Sep 2012 | — | Medical University of Vienna | Terminated | No outcome recorded |
| Phase 3 | NCT01306461 | Mar 2011 → Apr 2012 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01272609 | Feb 2011 → Sep 2012 | melanoma | Centre Hospitalier Universitaire de Nice | Terminated | No outcome recorded |
| Phase 3 | NCT01292460 | Feb 2011 → Sep 2012 | ocular hypertension, open-angle glaucoma | Santen Inc. | Completed | Met primary |
| Phase 3 | NCT00465803 | Mar 2007 → Jan 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00383019 | Nov 2006 → Oct 2007 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00546286 | May 2006 → Aug 2007 | ocular hypertension, open-angle glaucoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00277498 | Dec 2005 → Jun 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Mixed |
| Phase 3 | NCT00314158 | Nov 2005 → Jan 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 3 | NCT00230763 | Sep 2005 → Oct 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00159653 | Jul 2005 → Jun 2007 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00219596 | Jun 2005 → Sep 2006 | ocular hypertension, open-angle glaucoma | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00108017 | Apr 2005 → Jul 2006 | glaucoma, ocular hypertension | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00332059 | May 2003 → Sep 2004 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00061542 | Jan 2003 → Nov 2006 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00332540 | Aug 2001 → Aug 2003 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00332072 | Aug 2001 → Aug 2003 | ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00051155 | Jan 2001 → Jul 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00800267 | Jul 1997 → Jun 1999 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00006398 | Aug 1993 → Sep 2002 | cirrhosis of liver, esophageal varices, portal hypertension | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 3 | NCT02154217 | ? → Dec 2004 | glaucoma | University of Milan | Completed | Met primary |
| Phase 440 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07847073 | Oct 2026 → Jan 2028 expected | open-angle glaucoma | Brett King | Recruiting | No outcome recorded |
| Phase 4 | NCT07690397 | Jun 2026 → Jul 2027 expected | ocular hypertension, open-angle glaucoma | Tecnoquimicas | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05857267 | Mar 2023 → Nov 2024 | ocular hypertension, open-angle glaucoma | Laboratorios Poen | Completed | No outcome recorded |
| Phase 4 | NCT04702789 | Oct 2021 → Nov 2023 | ocular hypertension, open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded |
| Phase 4 | NCT06761313 | Mar 2021 → Dec 2024 overdue | glaucoma | Federal University of São Paulo | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04412096 | Nov 2020 → May 2025 | glaucoma, ocular hypertension | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT05299593 | Jun 2020 → Jun 2022 | ocular hypertension, open-angle glaucoma | Fondazione G.B. Bietti, IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT04098861 | Jan 2019 → Aug 2020 | open-angle glaucoma | Universiti Kebangsaan Malaysia Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02863705 | Jul 2016 → Jul 2018 | low tension glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02571712 | Nov 2015 → Jun 2018 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02053298 | Jan 2014 → Dec 2015 | open-angle glaucoma | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02003391 | Dec 2013 → May 2015 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 4 | NCT01677507 | Aug 2012 → Aug 2016 | glaucoma | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01518244 | Dec 2011 → Feb 2013 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01978015 | Oct 2011 → Jul 2012 | anterior uveitis, cystoid macular edema | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01484951 | May 2011 → Mar 2012 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01263444 | Mar 2011 → Apr 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01230736 | Oct 2010 → Feb 2011 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01159756 | Jul 2010 → Nov 2011 | ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01250457 | Jun 2010 → Jul 2012 | benign vascular tumor | Loyola University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01055366 | Mar 2010 → Dec 2011 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01151904 | Nov 2009 → Feb 2012 | angle-closure glaucoma | Allergan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00972426 | Oct 2009 → Aug 2010 | glaucoma | Taiwan Otsuka Pharm. Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00906087 | Aug 2009 → Jul 2012 | glaucoma | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00941096 | Jul 2009 → Nov 2010 | glaucoma, ocular hypertension | Larissa University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00957190 | May 2009 → Sep 2011 | eye disorder | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00869141 | Mar 2009 → Mar 2013 | glaucoma | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00759239 | Sep 2008 → Jan 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01155219 | Jul 2008 → Jul 2009 | glaucoma | Laboratoires Thea | Completed | No outcome recorded |
| Phase 4 | NCT00508469 | Oct 2007 → Jan 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00519753 | Aug 2007 → Dec 2008 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00545064 | May 2007 → Sep 2008 | ocular hypertension, open-angle glaucoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 4 | NCT00330577 | Apr 2006 → Apr 2007 | ocular hypertension, open-angle glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00273455 | Jan 2006 → May 2007 | open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00273442 | Nov 2005 → Apr 2007 | exfoliation syndrome, ocular hypertension, open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00273429 | Apr → Dec 2005 | ocular hypertension, open-angle glaucoma | Pharmaceutical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT00143208 | May 2003 → Apr 2006 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00348023 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable13 trials · 1 met primary | ||||||
| — | NCT05850936 | Jun 2023 → Nov 2026 expected | myopia | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| — | NCT05165082 | Dec 2021 → Jan 2023 | paronychia | Taipei Medical University WanFang Hospital | Completed | No outcome recorded |
| — | NCT04891588 | Mar → Sep 2021 | ocular hypertension, open-angle glaucoma | University Hospital Centre Zagreb | Unknown | No outcome recorded |
| — | NCT04296916 | Apr 2020 → Oct 2024 | borderline glaucoma, myopia | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03931317 | Dec 2018 → May 2021 | ocular hypertension, open-angle glaucoma | University of California, San Diego | Completed | No outcome recorded |
| — | NCT03220490 | Nov 2017 → Nov 2022 | glaucoma | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT02522039 | May → Nov 2014 | glaucoma | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
| — | NCT01843920 | Jun 2011 → Apr 2013 | — | Jason Hsu, MD | Completed | No outcome recorded |
| — | NCT01873131 | Feb 2011 → Dec 2025 overdue | hemangioma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT01506635 | Mar → Dec 2010 | myopia | Shahid Beheshti University of Medical Sciences | Completed | Met primary |
| — | NCT00275756 | Sep 2008 → Nov 2014 | glaucoma | Medical University of Vienna | Withdrawn | No outcome recorded |
| — | NCT00440336 | Oct 2006 → ? | open-angle glaucoma | Advanced Glaucoma Specialists | Unknown | No outcome recorded |
| — | NCT00435058 | Sep 2005 → Apr 2006 | glaucoma | University of Sao Paulo | Completed | No outcome recorded |
| Comparator or background therapy129 trials | ||||||
| Phase 0 | NCT01147601 Comparator | Mar 2010 → Oct 2012 | hemangioma | Oregon Health and Science University | Terminated | No outcome recorded |
| Phase 1 | NCT01845038 Comparator | Apr 2013 → Mar 2014 | glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01434888 Comparator | Sep → Dec 2011 | — | Santen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01215786 Comparator | Oct → Dec 2010 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 1/2 | NCT06120842 Comparator | Oct 2023 → Jan 2025 overdue | cataract, glaucoma, ocular hypertension | SpyGlass Pharma, Inc. | Active not recruiting | No outcome recorded |
| Show all 129 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-04 | Santen Gmbh | Regulatory Santen Announces China NMPA Approval of Tapcom🄬 in Patients with Open-Angle Glaucoma or Ocular Hypertension santen.com ↗ |
| 2023-02-08 | Santen Gmbh | Regulatory Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure santen.com ↗
Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure |
| 2015-10-02 | Sylentis, S.A. | Results Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in Glaucoma sylentis.com ↗
Bamosiran was very well-tolerated and treatment-related adverse events were more frequent in patients treated with timolol |
All press releases naming this drug 3 releases
Evidence & citations 45 cited values
Every value below carries the sentence it was read from. 257 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | timolol | “To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure...” NCT00159653 ↗221“From D1 to D10, each subject will receive one drop of 0.5% timolol maleate ophthalmic gel forming solution each in the left and right eyes once daily at the same time every day...” NCT06813807 ↗ “The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and...” NCT07036510 ↗ “Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.” NCT01159756 ↗ “The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia” NCT06321562 ↗ “This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment.” NCT00143208 ↗ “effects on tear film thickness of timolol with preservatives (Timoptic 0.5%) will be compared to timolol without preservatives (Timophtal sine 0.5%).” NCT01746602 ↗ “OBJECTIVE: To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy.” PMID 20142538 ↗ Feb 2010 “IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.” NCT05850936 ↗ “The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt)” NCT00140049 ↗ “a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID)” NCT01535768 ↗ |
| Known as | Aquanil | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Betim | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Betimol | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Blocadren | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Fixed Dose Combination of tafluprost and timolol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01306461 ↗ |
| Known as | Geltim LP | “Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel)” NCT01155219 ↗ |
| Known as | Glau-opt | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Glaucol | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Istalol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698945 ↗ |
| Known as | NSC-757351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Nyogel | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Ophtamolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | TGFS | “Timolol Gel-forming Solution (TGFS)” NCT00061542 ↗ |
| Known as | Tiloptic | “first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker).” NCT03220490 ↗ |
| Known as | TIM | “A total of 189 prior timolol users were randomized within the timolol stratum (TS) to receive either FC (n = 95) or timolol 0.5% (TIM; n = 94).” PMID 25447269 ↗ Dec 2014 |
| Known as | Timolol (as maleate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol eye drops 0.5% | “Drug: Timolol eye drops 0.5%” NCT07075718 ↗ |
| Known as | Timolol Gel-forming Solution (TGFS) | “Timolol Gel-forming Solution (TGFS)” NCT00061542 ↗ |
| Known as | Timolol hemihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol hydrogen maleate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | timolol malate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02863705 ↗ |
| Known as | timolol maleate | “The combination of the eye drops Bimatoprost 0.3%, Timolol Maleate 0.5%, and Brimonidine Tartrate 0.2% in separate vials is traditionally used in patients with difficult...” NCT06761313 ↗46“PURPOSE: To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% every evening (qpm) with timolol maleate...” PMID 26875002 ↗ Feb 2016 “PURPOSE: To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or...” PMID 27210275 ↗ May 2016 “Timolol maleate ophthalmic solution is an FDA-approved non-selective beta-adrenergic receptor blocking agent indicated for the treatment of ocular hypertension and open-angle glaucoma.” NCT07847073 ↗ “This study will examine the efficacy and safety of topically applied beta-antagonist Timoptic-XE® (timolol maleate ophthalmic gel forming solution) in subjects with DFUs.” PMID 32513257 ↗ Jun 2020 “the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.” PMID 21257146 ↗ Jan 2011 “compared three administrations of 10- or 15-µg bimatoprost implant (day 1, weeks 16 and 32) with twice-daily topical timolol maleate 0.5%.” PMID 35643967 ↗ May 2022 “Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).” NCT03519386 ↗ “Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops” NCT03966560 ↗ “One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks” NCT01026831 ↗ “Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution)” NCT00471068 ↗ |
| Known as | Timolol maleate 0.5% | “Timolol maleate 0.5%” NCT02731287 ↗ |
| Known as | Timolol maleate component of combigan | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol maleate component of cosopt | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol maleate component of duotrav | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol maleate component of ganfort | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol maleate component of xalacom | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol maleate, s-enantiomer | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timolol Maleate/Sorbitol Complex | “Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical)” NCT00698945 ↗ |
| Known as | Timololi maleas | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timoptic | “Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in...” NCT01446497 ↗4“Timolol (0.5%, non-selective beta-blocker, Timoptic®” NCT00275756 ↗ “Timolol 0.5% Ophthalmic Solution (Timoptic)” NCT00763061 ↗ |
| Known as | Timoptic in ocudose | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | Timoptic-XE | “Timoptic-XE” NCT03282981 ↗ |
| Known as | Timoptol | “carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)” NCT00972426 ↗ |
| Known as | Tiopex | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Known as | TM gel | “The goal of this clinical trial is to evaluate the safety and efficacy of timolol maleate (TM) gel in subjects with superficial infantile hemangioma (IH) in the proliferative phase.” NCT06677853 ↗ |
| Known as | WP-934 | ChEMBL registry synonym — accepted as the source's own label CHEMBL499 ↗ |
| Action | Inhibit | “Beta-2 adrenergic receptor antagonist” CHEMBL499 ↗ |
| Modality | Other / unclassified | “Timolol, a beta blocker” NCT02754596 ↗ |
| Route | Topical | “timolol maleate ophthalmic gel-forming solution” PMID 19683191 ↗ Aug 2009 |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL499 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL499 ↗ |